Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level686 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04971304 | Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars | completed | — | 16,506 | Catherine M. LockhartOTHER | 0 | Jul 27, 2023 | clinicaltrials |
| NCT05963334 | Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer | completed | Phase 1 / Phase 2 | 49 | Cairo UniversityOTHER | 1 | Jul 27, 2023 |
| NCT05372692 | Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer | completed | N/A | 3 | Weijia Fang, MDOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT04417192 | Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer(OLAPem) | completed | Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT03339765 | Self-Advocacy Serious Game in Advanced Cancer | completed | N/A | 78 | University of PittsburghOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT02482311 | Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours | completed | Phase 1 | 92 | AstraZenecaINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT02610075 | Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | completed | Phase 1 | 62 | AstraZenecaINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05005650 | Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy(SDLNOC) | completed | — | 121 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05300828 | Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer | completed | — | 600 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT00003308 | Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 22, 2023 | clinicaltrials |
| NCT00003518 | Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors | completed | Phase 2 | 44 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT01686256 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer | completed | Phase 1 | 12 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01689636 | Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients | completed | Phase 1 | 8 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01689714 | Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma | completed | Phase 2 | 16 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT03563781 | SEntine Lymph Node in earLY Ovarian Cancer (SELLY)(SELLY) | completed | N/A | 176 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT00001503 | Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease | completed | — | 1,031 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)(ARIEL2) | completed | Phase 2 | 491 | pharmaand GmbHINDUSTRY | 6 | Jun 12, 2023 | clinicaltrials |
| NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | completed | Phase 1 / Phase 2 | 136 | pharmaand GmbHINDUSTRY | 5 | Jun 9, 2023 | clinicaltrials |
| NCT01968213 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)(ARIEL3) | completed | Phase 3 | 564 | pharmaand GmbHINDUSTRY | 11 | Jun 9, 2023 | clinicaltrials |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | Phase 3 | 349 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT04902144 | Clinical Outcomes for Offering Genetic Testing in a Tiered Approach | completed | N/A | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | completed | Phase 3 | 596 | Tesaro, Inc.INDUSTRY | 15 | Jun 2, 2023 | clinicaltrials |
| NCT02063464 | Blood Collection From People With Ovarian Cancer | completed | — | 85 | National Cancer Institute (NCI)NIH | 1 | May 24, 2023 | clinicaltrials |
| NCT05868889 | Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD | completed | — | 43 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT03657043 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | completed | Phase 2 | 98 | Seagen Inc.INDUSTRY | 6 | May 6, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT00538031 | Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 52 | City of Hope Medical CenterOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT02258165 | Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer(IMAGE) | completed | — | 84 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Apr 18, 2023 | clinicaltrials |
| NCT02737787 | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT03073525 | A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers | completed | Phase 2 | 25 | Gradalis, Inc.INDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04630769 | FT516 and IL2 With Enoblituzumab for Ovarian Cancer | completed | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03507452 | First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | completed | Phase 1 | 36 | BayerINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT04041128 | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | completed | Early Phase 1 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT03287674 | TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | completed | Phase 1 / Phase 2 | 7 | Inge Marie SvaneOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03756818 | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT02166905 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | completed | Phase 1 / Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03464201 | Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study(GREKO III) | completed | Phase 2 | 16 | Grupo Español de Tumores Huérfanos e InfrecuentesOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03038100 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(IMagyn050) | completed | Phase 3 | 1,301 | Hoffmann-La RocheINDUSTRY | 22 | Feb 17, 2023 | clinicaltrials |
| NCT03639246 | Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | completed | Phase 1 | 53 | Aravive, Inc.INDUSTRY | 1 | Feb 13, 2023 | clinicaltrials |
| NCT03004391 | Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125 | completed | — | 25 | Vejle HospitalOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT03161132 | Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin(ROLANDO) | completed | Phase 2 | 32 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies(SIGN) | completed | Phase 2 | 116 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jan 26, 2023 | clinicaltrials |
| NCT02973750 | Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer | completed | — | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 26, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Jul 27, 2023source: clinicaltrials